NorthX Biologics expands cell therapy partnership with Alder Therapeutics

21-Jun-2022

Sweden-based NorthX Biologics is expanding into cell therapy manufacturing at its existing GMP facility as well as in premises at the Karolinska University Hospital campus in Stockholm

This initiative is part of NorthX’s Innovation Hub, an Innovation Track designed to provide development and GMP-manufacturing services to the next generation of drug development companies and innovative research groups in need of NorthX’s Good Manufacturing Practice (GMP) expertise.

“NorthX has one of Northern Europe’s largest clinical-grade manufacturing capacities for plasmid DNA, recombinant proteins, cell banking and associated gene therapy services and this expansion into cell therapy is a major step to complete our offering for innovative clients. We are especially excited to work with Dr Kristian Tryggvason, a leader in cell therapy technologies, and his team,” said Dr Ted Fjällman, CEO of NorthX.

After having built up BioLamina and its cell culture reagents that are used worldwide both in academia and industry, Dr Tryggvason recently launched his latest venture: Alder Therapeutics.

In addition to its own product development, the company now entered into an agreement to help NorthX expand its cell culture services to many new different cell types, including pluripotent stem cells.

The Alder team will also help to design and validate NorthX’s new process development and GMP-manufacturing labs in Matfors, alongside those being established at the Karolinska University Hospital campus in Stockholm.

“Our goal is to be able to offer synergies to both cell and gene therapy clients and to collaborate with them through our Innovation Track, in which we work hand in hand with our clients regarding process development, manufacturing, and analytics to progress clinical programs and bring life-saving treatments to patients,” added Aaron Small, NorthX VP of Global Sales and Corporate Development.

“Universities and cell therapy companies worldwide need GMP-grade development and manufacturing capacity, as it is complex and outside the scope of most biotech companies to build themselves."

Sign up for your free email newsletter

"NorthX Biologics is already helping to translate cutting-edge gene therapy research into clinical development and now we will together build upon the existing broad cell therapy know-how in Sweden to do the same for cell therapies,” said Dr Kristian Tryggvason, CEO Alder Therapeutics.

Companies